These results indicated that carvedilol treatment targeting the adrenergic overdrive in HFD-induced obesity effectively blocked the induction of gluconeogenic enzymes to suppress a hepatic glucose overproduction and enhanced the muscular insulin signaling pathway. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.